SAN FRANCISCO – Edwards Lifesciences Corp. said it's doubling down on a plan to be successful in the transcatheter mitral valve replacement (TMVR) market. The Irvine, Calif.-based company laid out what said is its 'shots on goal' strategy to penetrate the TMVR space, during the 35th annual J.P. Morgan Healthcare Conference. Read More
